
Sign up to save your podcasts
Or
Biopharmas developing therapies for obesity are looking to a future where the quality of weight loss matters as much as the quantity — what targets and programs could help realize that vision? On the latest BioCentury This Week podcast, BioCentury’s editors discuss the signaling pathways that may exclusively target fat mass while preserving, or even increasing, lean mass — and which companies are playing in the space.
The editors also assess what Vinay Prasad’s past comments say about how he might lead FDA’s Center for Biologics Evaluation and Research (CBER) — and examine how investors are evaluating the possibility that he might move the bar for regulatory approvals. The team then introduces the first in a new BioCentury series, with a look at a Literature Dive into ovarian cancer “atlases” — large-scale molecular profiling studies that point to predictive signatures and patient stratification strategies. This episode was sponsored by Jeito Capital.
View full story: https://www.biocentury.com/article/655898
#biotech #biopharma #pharma #obesity #FDA #CBER #LifeScience #OvarianCancer
00:01 - Sponsor Message: Jeito Capital
03:22 - Obesity: Quality over Quantity
15:47 - Prasad at FDA
27:58 - Ovarian Cancer Atlases
To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].
Reach us by sending a text
4.9
2828 ratings
Biopharmas developing therapies for obesity are looking to a future where the quality of weight loss matters as much as the quantity — what targets and programs could help realize that vision? On the latest BioCentury This Week podcast, BioCentury’s editors discuss the signaling pathways that may exclusively target fat mass while preserving, or even increasing, lean mass — and which companies are playing in the space.
The editors also assess what Vinay Prasad’s past comments say about how he might lead FDA’s Center for Biologics Evaluation and Research (CBER) — and examine how investors are evaluating the possibility that he might move the bar for regulatory approvals. The team then introduces the first in a new BioCentury series, with a look at a Literature Dive into ovarian cancer “atlases” — large-scale molecular profiling studies that point to predictive signatures and patient stratification strategies. This episode was sponsored by Jeito Capital.
View full story: https://www.biocentury.com/article/655898
#biotech #biopharma #pharma #obesity #FDA #CBER #LifeScience #OvarianCancer
00:01 - Sponsor Message: Jeito Capital
03:22 - Obesity: Quality over Quantity
15:47 - Prasad at FDA
27:58 - Ovarian Cancer Atlases
To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].
Reach us by sending a text
752 Listeners
2,173 Listeners
39 Listeners
122 Listeners
318 Listeners
59 Listeners
88 Listeners
147 Listeners
10 Listeners
38 Listeners
155 Listeners
3 Listeners
11 Listeners
51 Listeners
11 Listeners